The nausea timeline across the first four weeks, with a tabulated log posts 121–135

Timeline matters: onset, duration, pattern over days or weeks, relationship to injection and to meals all provide information that "I have nausea" does not. Posting those details gets better responses than reporting the symptom alone.

Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.

Picking up post #120: that is the part I would want checked first.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Coming back to post #122, because the follow-up matters more than the original answer.

Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.

Injection site reaction: local erythema, nodules, or induration at injection sites is reported by some people. Site rotation, avoiding reinjection into the same area for weeks, and allowing areas that react to recover all reduce the frequency.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

Hair shedding: telogen effluvium associated with rapid weight loss is reported. The timing usually correlates with the speed of weight change rather than the compound specifically. It is usually self-limiting.

I read post #126 twice before replying, because I had assumed the opposite.

Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance training volume, and total energy deficit. Adequate protein and maintaining training intensity both help preserve lean mass during weight reduction.

On post #126 — agreed on the reasoning, with one qualification.

Pancreatitis: a rare but serious event with a specific presentation (epigastric pain, back pain, elevated lipase). If this constellation of findings appears, stopping the drug and seeking immediate evaluation is appropriate. Do not interpret this as "likely" — it is rare — but recognize the pattern if it appears.

Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.

Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.

Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before attributing all of it to the compound. Some fatigue resolves with time; some persists.

post #133 is right about the mechanism and I think understates the practical bit.

Timeline matters: onset, duration, pattern over days or weeks, relationship to injection and to meals all provide information that "I have nausea" does not. Posting those details gets better responses than reporting the symptom alone.